FIJYX Performance — Fidelity Advisor Biotechnology Fund, Class Z
Data updated: 2026-10-13
FIJYX returned +20.89% year to date and +62.84% over one year to Jul 2026. Annualised returns are +25.12% over 3 years and +13.02% over 5 years. The fund beat its Health Care Equity category average: $100 invested three years ago grew to $196, against $137 for the category, and to $163 over one year, against $137. Volatility over the past three years was 21.90% a year. In the 12 months to Jul 2026 the fund lost a net $22.5M, and assets reached $2.20B.
FIJYX Growth of $100
What $100 invested in Fidelity Advisor Biotechnology Fund grew to, compounded from monthly returns reported on SEC Form N-PORT, against the Health Care Equity category average over the same months.
| Period | FIJYX | Category average |
|---|---|---|
| 1 year (Aug 2025 – Jul 2026) | $163 | $137 |
| 3 years (Aug 2023 – Jul 2026) | $196 | $137 |
| 5 years (Aug 2021 – Jul 2026) | $184 | $121 |
| Since data start (Aug 2019 – Jul 2026) | $275 | $183 |
FIJYX Trailing Returns
Total returns to Jul 2026, from SEC N-PORT.
| Period | Total return |
|---|---|
| YTD | +20.89% |
| 1 year | +62.84% |
| 3 years (annualised) | +25.12% |
| 5 years (annualised) | +13.02% |
FIJYX Annual Returns
Calendar-year total returns of Fidelity Advisor Biotechnology Fund, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2026 (Jan–Jul) | +20.89% |
| 2025 | +40.11% |
| 2024 | +5.73% |
| 2023 | +11.16% |
| 2022 | −7.60% |
| 2021 | −3.23% |
| 2020 | +32.53% |
| 2019 (Aug–Dec) | +16.62% |
FIJYX Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +1.4% | +2.2% | −1.3% | +2.1% | +0.6% | +15.8% | −0.7% | — | — | — | — | — |
| 2025 | +1.0% | −0.6% | −5.1% | +0.6% | −3.1% | +3.6% | +8.1% | +5.9% | +10.9% | +8.6% | +10.7% | −4.6% |
| 2024 | +4.2% | +6.6% | +2.0% | −8.9% | +1.7% | +4.5% | +7.9% | +3.1% | +0.5% | +0.5% | −6.1% | −8.6% |
| 2023 | +1.2% | −3.5% | −2.3% | +3.3% | +0.3% | +0.5% | +2.3% | −2.9% | −4.1% | −5.6% | +4.2% | +19.5% |
| 2022 | −12.7% | +0.3% | +4.9% | −13.1% | −6.1% | +5.5% | +2.7% | +8.5% | −1.9% | +5.5% | +1.7% | −0.3% |
| 2021 | +0.6% | +0.6% | −4.7% | +1.4% | −4.9% | +5.6% | −1.8% | +8.7% | −5.0% | +1.2% | −6.2% | +2.4% |
| 2020 | −5.2% | +0.4% | −6.9% | +14.8% | +11.1% | +2.3% | −3.3% | +1.9% | +1.2% | −1.8% | +12.6% | +4.1% |
| 2019 | — | — | — | — | — | — | — | −1.7% | −3.0% | +6.7% | +11.5% | +2.9% |
FIJYX Risk
Risk measures from monthly returns over Aug 2023 – Jul 2026.
- 3-year volatility (annualised): 21.90%
- 3-year Sharpe ratio: 0.94 (vs 4.5% risk-free rate)
- Best month: +19.49% (Dec 2023)
- Worst month: −8.91% (Apr 2024)
FIJYX Fund Flows
Monthly money in and out of Fidelity Advisor Biotechnology Fund, from SEC Form N-PORT.
- 12-month net flow: −$22.5M
- 12-month gross sales (incl. reinvestments): $320.8M
- Sales ÷ redemptions: 0.93×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| Jul 2026 | $42.1M | $28.9M | $13.2M |
| Jun 2026 | $27.9M | $27.8M | $95K |
| May 2026 | $16.4M | $28.0M | −$11.6M |
| Apr 2026 | $18.8M | $25.9M | −$7.0M |
| Mar 2026 | $19.0M | $24.8M | −$5.8M |
| Feb 2026 | $25.7M | $29.6M | −$4.0M |
| Jan 2026 | $24.4M | $27.8M | −$3.4M |
| Dec 2025 | $53.3M | $27.5M | $25.8M |
| Nov 2025 | $33.2M | $26.7M | $6.5M |
| Oct 2025 | $25.9M | $31.1M | −$5.2M |
| Sep 2025 | $16.4M | $28.1M | −$11.6M |
| Aug 2025 | $17.6M | $37.0M | −$19.4M |
FIJYX Assets Under Management
Net assets of Fidelity Advisor Biotechnology Fund by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2026-07-31 | $2.20B |
| 2026-04-30 | $1.90B |
| 2026-01-31 | $1.87B |
| 2025-10-31 | $1.74B |
| 2025-07-31 | $1.40B |
| 2025-04-30 | $1.37B |
| 2025-01-31 | $1.54B |
| 2024-10-31 | $1.88B |
| 2024-07-31 | $1.81B |
| 2024-04-30 | $1.63B |
| 2024-01-31 | $1.68B |
| 2023-10-31 | $1.36B |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.